Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016034 | 0.93 | MEN1 (0.43) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL5429121 | 0.90 | MEN1 (0.41) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL3083396 | 0.90 | MEN1 (0.44) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL13632346 | 0.88 | MEN1 (0.43) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL13632342 | 0.88 | MEN1 (0.43) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL2318967 | 0.88 | MEN1 (0.43) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL24480263 | 0.84 | KMT2A (0.36) | HRH3KCNH2MEN1KMT2ATFPI2 | |
| SCHEMBL29336538 | 0.84 | HRH3 (0.41) | HRH3 | |
| SCHEMBL1784015 | 0.84 | L3MBTL1 (0.41) | HRH3KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL25612894 | 0.84 | ADH1B (0.52) | HRH3KCNH2MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219502-A1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS | BeiGene, Ltd. (KY) | 2023-08-02 | — | — | EP | disclosed |
| CN-111377907-B | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-111377907-A | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020135507-A1 | POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | 杭州百新生物医药科技有限公司 | 2020-07-02 | — | — | WO | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HRH3 166/4885KCNH2 2437/4885MEN1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.